Reshaping our perception of the typical hospitalized heart failure patient: A gender analysis of data from the adhere heart failure registry

Journal of Cardiovascular Nursing

Volumn 20, Issue 6, 2005, Pages 442-450

  Galvao, Marie ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Gender; Heart failure; Preserved left ventricular function

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ANALYSIS OF VARIANCE; ARTICLE; CONGESTIVE HEART FAILURE; DISEASE MANAGEMENT; FEMALE; HEALTH CARE QUALITY; HEART LEFT VENTRICLE FUNCTION; HOSPITAL DISCHARGE; HUMAN; MALE; PATHOPHYSIOLOGY; REGISTER; SEX DIFFERENCE; SMOKING CESSATION; STATISTICS; UNITED STATES;

AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE MANAGEMENT; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; PATIENT DISCHARGE; QUALITY INDICATORS, HEALTH CARE; QUALITY OF HEALTH CARE; REGISTRIES; SEX FACTORS; SMOKING CESSATION; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33644870008     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200511000-00013     Document Type: Article

References (67)

1. 2004 Heart Disease and Stroke Statistics Update. Dallas, TX: American Heart Association; 2004.
2. Patel H, Rosengren A, Ekman I. Symptoms in acute coronary syndromes: does sex make a difference? Am Heart J. 2004;148(1):27-33.
3. Young L, Little M. Women and heart transplantation: an issue of gender equity. Health Care Women Int. 2004;25(5):436-453.
4. Kattainen A, Reunanen A, Koskinen S, Martelin T, Knekt P, Aromaa A. Disability predicted mortality in men but not women with coronary heart disease. J Clin Epidemiol. 2004;57(5):513-521.
5. Raggi P, Shaw LJ, Berman DS, Callister TQ. Gender-based differences in the prognostic value of coronary calcification. J Women's Health (Larchmt). 2004;13(3):273-283.
6. Adams KF Jr, Sucia CA, Gheorghiade M, et al. Gender differences in survival in advanced heart failure: insights from the FIRST study. Circulation. 1999;99:1816-1821.
7. Casper ML, Barnett E, Halverson JA, et al. Women and Heart Disease: An Atlas of Racial and Ethnic Disparities in Mortality. 2nd ed. Morgantown, WV: Office for Social Environment and Health Research, West Virginia University; 2000.
8. Trupp R. It's Time to make women's cardiovascular health a priority. J. Cardiovasc Nurs. 2005;20(6):373.
9. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343:475-480.
10. Petrie MC, Dawson NF, Murdoch DR, Davie AP, McMurray JJV. Failure of women's hearts. Circulation. 1999;99:2334-2341.
11. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol. 1997;30:1417-1419.
12. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682-1688.
13. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1992;268(11):1417-1422.
14. Miller CL, Kollauf CR. Evolution of information on women and heart disease 1957-2000: a review of archival records and secular literature. Heart Lung. 2002;31F(4):253-261.
15. Silber DH. Heart failure in women. Curr Women's Health Rep. 2003;3(2):104-109.
16. Simon T, Mary-Krause M, Funck-Brentano C, et al. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation. 2001;103:375-380.
17. Adams KF, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol. 1996;28(7):1781-1788.
18. Kimmelstein CD, Konstam MA. Heart failure in women. Cardiology. 1995;86:304-309.
19. McKee P, Castelli WP, McNamara PM, Kannel WB. Natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446.
20. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in the Framingham Heart Study subjects. Circulation. 1993;88:107-115.
21. Ghali JK, Krause-Steinrauf HJ, Adams KF, et al. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol. 2003;42(12):2128-2134.
22. Diller PM, Smucker DR, David B, Graham RJ. Congestive heart failure due to diastolic or systolic dysfunction. Arch Fam Med. 1999;8:414-420.
23. Buttrick P, Scheuer J. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation. 1992;86(4):1336-1338.
24. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE®): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21-S30.
25. JCAHO. Specifications Manual for National Implementation of Hospital Core Measures. Oakbrook Terrace, IL: Joint Commission on Accreditation of Heathcare Organizations; 2004.
26. Klapholz M, Maurer M, Lowe AM, et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol. 2004;43(8):1432-1438.
27. CDC. Health, United States, 2003, Table 27. Life Expectancy at Birth, at 65 Years of Age, and at 75 Years of Age, According to Race and Sex: United States, Selected Years 1900-2001. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Health Statistics; 2003.
28. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111(2):383-390.
29. Koelling TM, Chen RS, Lubwama RN, L'Italien GJ, Eagle KA. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J. 2004;147(1):74-78.
30. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation. 2000;102(25):3137-3147.
31. Pijna IL, Buchter C. Heart failure in women. Cardiol Rev. 2003;11(6):337-344.
32. Halm MA, Penque S. Heart failure in women. Prog Cardiovasc Nurs. 2000;15(4):121-133.
33. Limacher MC, Yusef S, for the SOLVD Investigators. Gender differences in presentation, morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD): a preliminary report. In: Wenger NK, Speroff I, Packard B, eds. Cardiovascular Health and Disease in Women. Greenwich, CT: Le Jacq Communications, 1993;345-348.
34. Chin MH, Goldman L. Gender differences in 1-year survival and quality of life among patients admitted with congestive heart failure. Med Care. 1998;36(7):1033-1046.
35. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 1990;38:1290-1395.
36. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
37. The Smoking Cessation Clinical Practice Guideline Panel and Staff: The Agency for Healthcare Policy and Research. Smoking cessation clinical practice guideline. JAMA. 1996;275:1270-1380.
38. Lee WY, Capra AM, Jensvold NG, Gurwitz JH, Go AS. Epidemiology, Practice, Outcomes, and Cost of Heart Failure (EPOCH) Study. Gender and risk of adverse outcomes in heart failure. Am J Cardiol. 2004;94(9):1147-1152.
39. Babayan ZV, McNamara YL, Nagajothi N, et al. Predictors of cause-specific hospital readmission in patients with heart failure. Clin Cardiol. 2003;26(9):411-418.
40. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol. 2001;88(5):530-533.
41. Davidson PM, Daly J, Hancock K, Moser D, Chang E, Cockburn J. Perceptions and experiences of heart disease: a literature review and identification of a research agenda in older women. Eur J Cardiovasc Nurs. 2003;2(4):255-264.
42. Kennedy MD, Haykowsky M, Daub B, Van Lohuizen K, Knapik G, Black B. Effects of a comprehensive cardiac rehabilitation program on quality of life and exercise tolerance in women: a retrospective analysis. Curr Control Trials Cardiovasc Med. 2003;4(1):1.
43. Ades PA, Waldmann ML, Polk DM, Coflesky JT. Referral patterns and exercise response in the rehabilitation of female coronary patients aged greater than or equal to 62 years. Am J Cardiol. 1992;69(17):1422-1425.
44. American Heart Association. Go Red for Women for Professionals. Available at:. Accessed June 28, 2004.
45. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail. 1999;5(4):357-382.
46. Gass AL, Hermann L, Collins SP, Mills RM, Valerio L. Critical Pathways in the Management of Acute Decompensated Heart Failure: A CME-Accredited Monograph. 2004. >Med Reviews LLC>.
47. Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 suppl):V124-V131.
48. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol. 1988;62(2):60A-66A.
49. Bangdiwala SI, Weiner DH, Bourassa MG, Friesinger GC 2nd, Ghali JK, Yusuf S. Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics. Am J Cardiol. 1992;70(3):347-353.
50. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468-1475.
51. Massie BM, Fisher SG, Radford M, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation. 1996;93(12):2128-2134.
52. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335(15):1107-1114.
53. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44-54.
54. Girbes AR, Zijlstra JG. Ibopamine and survival in severe congestive heart failure: PRIME II. Lancet. 1997;350(9071):147-148.
55. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-533.
56. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349(9054):747-752.
57. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339(25):1810-1816.
58. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
59. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):1295-1302.
60. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312-2318.
61. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-717.
62. Pitt B, Poole-Wilson P, Segal R, et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study-ELITE II. J Card Fail. 1999;5(2):146-154.
63. Cohn JN, Tognoni G, Glazer R, Spormann D. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur J Heart Fail. 2000;2(4):439-446.
64. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194-2199.
65. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13.
66. McMurray J, Ostergren J, Pfeffer M, et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity (CHARM) programme. Eur J Heart Fail. 2003;5(3):261-270.
67. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION)trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail. 2000;6(3):276-285.